Abstract
Introduction
Classification of primary CNS solitary fibrous tumour/hemangiopericytoma (SFT/HPC) has been recently redefined by the latest World Health Organization (WHO) Classification of Tumours of the Central Nervous System (CNS) [1] by merging into a single category two previously separated diagnostic entities (solitary fibrous tumour and hemangiopericytoma). This change mirrors what was already accepted for SFT/HPC of other sites (e.g. soft tissues and pleura) and is supported by a shared molecular hallmark: the chromosomal inversion at the 12q13 locus, fusing the NGFI-A-binding protein 2 (NAB2) and the signal transducer and activator of transcription 6 (STAT6) genes [2, 3] . This alteration is indeed present in most SFT/ HPC cases regardless of tumour site or grade. NAB2-STAT6 fusion protein promotes tumour growth by localizing to the nucleus and activating the EGR gene. Nuclear localization of the fusion protein can be detected by anti-STAT6 antibodies [4] and STAT6 immunohistochemistry (IHC) is currently a recommended diagnostic tool by the latest WHO classification, since no nuclear STAT6 staining is present in meningiomas or in other frequent meningeal tumours, thus helping in the differential diagnosis. [1, 4] CNS SFT/HPC are rare (less than 1% of all primary CNS tumours), usually dural-based intracranial tumours, thought to develop from CD34-positive fibroblasts present in the dura mater or in the intraparenchymal perivascular connective tissue [5, 6] and mostly occur in adults, with a slightly higher incidence in males. [7] Exact epidemiological data are difficult to ascertain, due to both their rarity and to the changes of classification criteria over time.
Prognosis is often good, especially in cases with the solitary fibrous tumour morphology and when gross total resection is achieved; conversely, the hemangiopericytoma morphology is associated with a higher rate of local recurrences (>75% in patients with long term follow up) and distant metastases occurrence. [8] [9] [10] [11] [12] Based on these findings, the current WHO grading criteria provide that SFT/HPC with solitary fibrous tumour phenotype and mitotic count <5 mitoses/10 high-power fields (HPF) are classified as grade I, whereas tumours with hemangiopericytoma morphology are graded as grade II or III based on the mitotic count with a cutoff value of 5 mitoses/10 HPF. [1] Radiotherapy may be of benefit to patients with incomplete resection or at higher risk of recurrence. [13, 14] Overall, compared to extra-CNS SFT/HPC, prognostic markers are less defined and available data are limited by the rarity of this tumour; thus, new and reliable prognostic factors are warranted to help personalize patients' therapeutic management. Therefore, we wanted to retrospectively assess novel possible prognostic factors in a series of SFT/HPC diagnosed at our Institution, evaluating both histopathological and molecular features. In particular, we evaluated the prognostic relevance of two IHC markers: CD34 and B-cell lymphoma 2 (Bcl-2), which, although non-specific, can be useful diagnostic tools and were especially important in the pre-STAT6 era. [15] CD34 loss has been reported as a characteristic finding in dedifferentiated extra-CNS SFT. [16] Secondly, considered the prognostic relevance of mitotic count in this tumour entity, we wanted to evaluate if a count based on phosphorylated histone H3 (PHH3) IHC could improve its grading and prognostic capability compared to H&E-based mitotic count. PHH3 antibody specifically recognizes the phosphorylated (at serines 10 and 28) histone H3, which is present in cells at the end of G2 or in the M phase of cell cycle and it has already been validated as a useful IHC marker to improve mitotic count sensitivity in different types of neoplasms, including breast cancer and meningiomas. [17, 18] In terms of molecular profile, telomerase maintenance has been recently described as a hallmark of most human cancers, needed by neoplastic cells to escape replicative senescence. TERT gene codes for the catalytic subunit of the telomerase complex and recurrent point mutations of its promoter have been shown to create a novel binding site for E-twenty-six (ETS) family transcription factors, leading to increased telomerase activity in affected cells. TERT promoter mutations are common to different malignancies, with variable prognostic significance. [19] [20] [21] [22] Since this molecular alteration seems to be associated with adverse outcome in extra-CNS SFT, [23] we wanted to explore its possible prognostic meaning in our series. Written informed consent was not obtained because patients were no longer undergoing regular follow up visits directly at our institution or were deceased; considered the retrospective nature of the present study and that it had no impact at all on patients' care, verbal informed consent was obtained from participants or their relatives and recorded in a specific log. This study, including the verbal consent procedure, was approved by the Research Ethics Committee of the University of Turin.
Materials and methods

Case series and tissue samples
Morphology and immunohistochemistry
All diagnoses were confirmed by a senior neuropathologist (PC) and reassessed according to the 2016 WHO classification. Thus, tumours were graded based on their phenotype (solitary fibrous tumour versus hemangiopericytoma) and mitotic count on H&E slides. Mitotic count was repeated after PHH3 IHC (polyclonal, Ventana Medical Systems Inc., Tucson, AZ, US). IHC for STAT6 (polyclonal, Spring Bioscience Corporation, Pleasanton, CA, US), Ki67 (clone 30-9, Ventana Medical Systems Inc., Tucson, AZ, US), CD34 (clone QBEnd/10, Ventana Medical Systems Inc., Tucson, AZ, US) and Bcl-2 (clone SP66, Ventana Medical Systems Inc., Tucson, AZ, US) were also performed. Immunohistochemistry for Ki67, CD34 and Bcl-2 was performed on all tissue blocks of each case; Ki67 labelling index was evaluated by counting at least 1000 tumour cells while CD34 and Bcl-2 were assessed by visual estimation. Nuclear staining for STAT6 was considered consistent with the SFT/HPC diagnosis. BenchMark ULTRA platform (Ventana Medical Systems Inc., Tucson, AZ, USA) was used for all IHC.
TERT promoter sequencing
DNA extraction from formalin-fixed and paraffin-embedded (FPPE) tumour samples was performed as previously described [24] and concentrations/purity were measured by a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
Mutational status of the telomerase reverse transcriptase (TERT) promoter region from position -27 to -286 from ATG start site, including the polymorphic site represented by rs2853669, were determined by PCR and Sanger sequencing using the following primer pair: promoter forward 5 0 -CAGCGCTGCCTGAAACTC-3 0 and reverse 5 0 -GTCCTGCCCCTT CACCTT-3 0 , as described by Horn et al. [25] PCR products were purified and used as template for the sequencing reactions, which were performed with BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). After purification, the sequences were analyzed by Sanger direct sequencing using the ABIPRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 
Statistical analyses
Results
Clinical characteristics
Fifteen SFT/HPC cases were retrospectively collected: 9/15 (60%) were female, median age at diagnosis was 60 (range: 10-67). Median follow up time was 2.4 years (6 months-7.4 years). Gender, age and tumour site were not significantly correlated with tumour morphology/phenotype (Table 1) . Tumour site was as follows: cranial base 8/15 (53%), cerebral hemispheres 4/ 15 (27%) and posterior fossa 3/15 (20%). Gross total resection was not achieved in 7/15 (47%) and in 4 of these cases (57%), tumour was located at cranial base. Five patients (33%) developed local disease recurrence, but none showed distant metastases; all patients with disease recurrence had an incomplete surgical resection. Ten patients out of 15% (66%) were alive at end of follow up, whereas 5 patients died (3/5 because of SFT/HPC progression, 2/5 due to other causes). Gross total resection was significantly associated with a more favourable disease-free interval (DFI) (log-rank test p = 0.0185) (Fig 1A) , while no correlation was found for age, gender or tumour site.
Histological features and grading
Six cases showed a solitary fibrous tumour phenotype (6/15, 40%) (Fig 2A, (Fig 1B) , while tumour phenotype did not (logrank test p = 0.062) (Fig 1C) .
PHH3-based grading
Although the mean number of mitoses/10 HPF observed following PHH3 IHC staining was higher than in H&E (8.4 versus 4.8, SD: 10.69) (Fig 2C) , in one case only the PHH3-based mitotic count would have changed the tumour grade (from grade II to III) according to the WHO criteria. As observed for the H&E-based count, PHH3-based mitotic count !5/10 HPF significantly correlated with the hemangiopericytoma phenotype (p = 0.028). WHO grade using PHH3-based mitotic count was not significantly associated with DFI (log-rank test p = 0.094) (Fig 1D) .
Immunohistochemistry
Nuclear staining for STAT6 was present in 14/15 (93.3%) (Fig 2D) . The only STAT6-negative case displayed the characteristic features of the hemangiopericytoma phenotype and was (Fig 2E and 2F) , overall mean number of positive cells was 64% (SD: 35.6%): mean rates of 86%, 90% and 19% positive cells were observed in grade I, II and III tumours, respectively (p<0.001). In 3/5 (60%) recurrent cases CD34 expression was <10%. Bcl-2 overall mean expression was 63% (SD: 38.6%), 74%, 76% and 38% in grade I, II and III tumours, respectively (p = 0.2262). Ki67 labelling index (p = 0.003) and CD34 expression (p = 0.025) were significantly correlated with the hemangiopericytoma phenotype (Table 1 ). CD34 expression 80% was associated with poorer DFI (log-rank test p = 0.038) (Fig 1E) as well as Bcl-2 expression 30% (log-rank test p = 0.010) (Fig 1F) .
TERT promoter sequencing
TERT promoter was successfully analysed in twelve cases out of 15 (80%) (one case was excluded because of lacking adequate material for analysis and in the other two cases sequencing failed). TERT promoter resulted wildtype in 10/12 (83%) cases, while 2/12 (17%) were mutated: the recurrent 1,295,228 C>T (C228T) mutation and a 1,295,254 C>T (C254T) mutation positioned respectively at 124 and 150 base pairs upstream of the ATG translational start site of TERT were identified; these mutations were found in a grade I and a grade II SFT/HPC, respectively. The first patient had no disease recurrence (follow up: 73 months), while the second patient had no recurrence too, but died of unrelated causes 5 months after diagnosis. Six out of 12 (50%) cases harboured the rs2853669 single nucleotide polymorphism (SNP). Neither of these findings was associated with tumour phenotype (p = 1.000 and p = 0.248) or DFI (log-rank test p = 0.387 and p = 0.739).
Discussion
The identification of prognostic markers is a crucial issue for appropriate patients' management, even more when it applies to rare entities or after changes in the classification criteria. Since SFT/HPC of the CNS well resume both these issues, in the present study we analysed and identified putative prognosticators which could be used in the daily practice. Prognostic factors are especially needed in this setting considered that some of the parameters used for risk-stratification of extra-CNS SFT/HPC, like tumour size, are not applicable in the CNS. [26] Beginning with clinical variables, GTR was significantly associated with a better DFI, a finding consistent with literature data. [8, 12, 27] As previous studies have found, surgical resection alone is sufficient to cure patients in many cases. Although tumour site was not related to DFI in our series, 57% of cases in which GTR was not achieved were located at cranial base, a site which could possibly hamper a complete resection as reported for other CNS tumours (i.e. meningiomas). [28] Among clinical variables neither gender nor age were related to patients' outcome.
Focusing on histopathological features, the two different tumour phenotypes (SFT and HPC) were not specifically associated with clinical variables (gender, age and tumour site): as a matter of fact, a distinction based on their clinico-radiological characteristics was not deemed possible even when they were considered different entities. [29] The HPC phenotype was associated with a higher mitotic count, but tumour phenotype alone did not reach statistical significance in terms of DFI; on the contrary, a higher WHO grade was associated with a worse outcome. This finding supports the present WHO grading criteria which take into account both tumour phenotype and mitotic count.
In our series, PHH3-based mitotic count was higher than the H&E-based (as expected), but it would have changed the WHO grade (from grade II to grade III) in one case, only; moreover, grading based on this tool was not associated with a different DFI, therefore suggesting its lack of utility in this specific subset of tumours. These results need to be validated in a larger cohort, but for the time being the use of PHH3-based mitotic count in daily practice is not supported.
Among other IHC markers, STAT6 nuclear staining was detected in all cases except for one (14/15, 93.3%), a finding consistent with literature data. [15] Rare STAT6-negative SFT/HPC are possible and in these cases diagnosis should be based on a careful revision of tumour morphology and using other markers like CD34, Bcl-2 and CD99. In terms of prognostic meaning, we found that a lower CD34-expressions was associated with a significantly poorer outcome in our series. Previous research studies found an association between CD34 loss and higher-grade tumours [30, 31] and decreased CD34 expression is also linked to recurrent tumours, a finding confirmed by our data: we observed a very low (<10%) CD34-expression in most of our recurrent cases (3/5, 60%). Bcl-2 expression (when lower than 30%) was associated with prognosis as well. In our series, only one of the 5 recurrent cases showed discordant CD34/Bcl-2 expression with low CD34 and high Bcl-2 expressions. This finding suggests a relationship between these two markers and is worth being validated in a larger series.
TERT promoter mutations have been identified in CNS SFT/HPC, but specific data in this setting are limited. [32, 33] In our cases, we observed a lower overall mutation rate compared to previously reported data (16.7% versus 25.6%), a difference even greater when considering the HPC phenotype alone (16.7% versus 50%). [32] We did not observe an association between TERT promoter mutational status and outcome, but this could probably be explained by the limited sample size. Moreover, one of the two identified mutations (C254T) was still unreported in this tumour entity. We also investigated a common TERT promoter SNP (rs2853669): its frequency in our series (50%) is in line with its prevalence in the general population and we did not observe an association with outcome.
In conclusion, WHO grade is the main prognostic tool for CNS SFT/HPC, but our data suggest that it could be integrated in the daily practice by other markers, like CD34 and Bcl-2. Also molecular traits, like TERT promoter mutations, could provide valuable information, but their significance in this setting needs further evaluation in larger series.
